Loading...
Loading...
CYTH| Name | Value |
|---|---|
| Revenues | 202.4K |
| Cost of Revenue | 836.5K |
| Gross Profit | -634.0K |
| Operating Expense | 4,475.2K |
| Operating I/L | -5,109.2K |
| Other Income/Expense | 766.2K |
| Interest Income | 0.0K |
| Pretax | -4,343.1K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,343.1K |
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company specializing in cyclodextrin-based products for treating Niemann-Pick Type C disease and Alzheimer's disease. Its lead drug candidate, Trappsol Cyclo, is in Phase III clinical trials for Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries for use in diagnostics and specialty drugs.
